4.6 Article

Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009

Journal

CANCER MEDICINE
Volume 4, Issue 4, Pages 608-619

Publisher

WILEY
DOI: 10.1002/cam4.410

Keywords

Central nervous system; childhood cancer; leukemia; years of life lived with disease; years of potential life lost

Categories

Funding

  1. National Institutes of Health [K12 CA076917]
  2. Dana Foundation (David Mahoney Neuroimaging Award)
  3. Neurofibromatosis Therapeutic Acceleration Program (Francis S. Collins Scholar Program)
  4. St. Baldrick's Foundation (Scholar Award)
  5. Pediatric Brain Tumor Foundation of the United States (PBTFUS)

Ask authors/readers for more resources

Incidence and survival rates are commonly reported statistics, but these may fail to capture the full impact of childhood cancers. We describe the years of potential life lost (YPLL) and years of life lived with disease (YLLD) in children and adolescents who died of cancer in the United States to estimate the impact of childhood cancer in the United States in 2009. We examined mortality data in 2009 among children and adolescents <20years old in both the National Vital Statistics System (NVSS) and the Surveillance, Epidemiology, and End Results (SEER) datasets. YPLL and YLLD were calculated for all deaths due to cancer. Histology-specific YPLL and YLLD of central nervous system (CNS) tumors, leukemia, and lymphoma were estimated using SEER. There were 2233 deaths and 153,390.4 YPLL due to neoplasm in 2009. CNS tumors were the largest cause of YPLL (31%) among deaths due to cancer and were the cause of 1.4% of YPLL due to all causes. For specific histologies, the greatest mean YPLL per death was due to atypical teratoid/rhabdoid tumor (78.0years lost). The histology with the highest mean YLLD per death in children and adolescents who died of cancer was primitive neuroectodermal tumor (4.6years lived). CNS tumors are the most common solid malignancy in individuals <20years old and have the highest YPLL cost of all cancers. This offers the first histology-specific description of YPLL in children and adolescents and proposes a new measure of cancer impact, YLLD, in individuals who die of their disease. YPLL and YLLD complement traditional indicators of mortality and help place CNS tumors in the context of other childhood malignancies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available